3/14/2013

The FDA granted a fast-track status to Chimerix's CMX001 for prevention of cytomegalovirus infection. The drug previously received a fast-track designation for smallpox and adenoviral disease in post hematopoietic stem cell transplant patients. CMX001 prevents double-stranded DNA viruses from replicating.

Related Summaries